Recursion Pharmaceuticals Prices $200 Million Public Offering

Key Facts

Recursion Pharmaceuticals priced a public offering of its common stock for total gross proceeds of $200 million. Investing.com reported that the company is raising this capital through a follow-on equity offering, which is typically directed toward general corporate purposes or the funding of research and development initiatives.

RXRX closed at $3.74 on October 14, 2026, having reached a day high of $3.91 and a low of $3.66 during that session. The pricing of the offering follows a period of market interest in the biotech sector, though such capital raises often introduce short-term bearish sentiment due to the potential dilution of existing shares.